Computational gene

Last updated
Figure 1: Design of a computational gene Computational Gene.jpg
Figure 1: Design of a computational gene

A computational gene [1] [2] [3] is a molecular automaton consisting of a structural part and a functional part; and its design is such that it might work in a cellular environment.

Contents

The structural part is a naturally occurring gene, which is used as a skeleton to encode the input and the transitions of the automaton (Fig. 1A). The conserved features of a structural gene (e.g., DNA polymerase binding site, start and stop codons, and splicing sites) serve as constants of the computational gene, while the coding regions, the number of exons and introns, the position of start and stop codon, and the automata theoretical variables (symbols, states, and transitions) are the design parameters of the computational gene. The constants and the design parameters are linked by several logical and biochemical constraints (e.g., encoded automata theoretic variables must not be recognized as splicing junctions). The input of the automaton are molecular markers given by single stranded DNA (ssDNA) molecules. These markers are signalling aberrant (e.g., carcinogenic) molecular phenotype and turn on the self-assembly of the functional gene. If the input is accepted, the output encodes a double stranded DNA (dsDNA) molecule, a functional gene which should be successfully integrated into the cellular transcription and translation machinery producing a wild type protein or an anti-drug (Fig. 1B). Otherwise, a rejected input will assemble into a partially dsDNA molecule which cannot be translated.

A potential application: in situ diagnostics and therapy of cancer

Computational genes might be used in the future to correct aberrant mutations in a gene or group of genes that can trigger disease phenotypes. [4] [ self-published source? ] One of the most prominent examples is the tumor suppressor p53 gene, which is present in every cell, and acts as a guard to control growth. Mutations in this gene can abolish its function, allowing uncontrolled growth that can lead to cancer. [5] For instance, a mutation at codon 249 in the p53 protein is characteristic for hepatocellular cancer. [6] This disease could be treated by the CDB3 peptide which binds to the p53 core domain and stabilises its fold. [7]

A single disease-related mutation can be then diagnosed and treated by the following diagnostic rule:

if protein X_mutated_at_codon_Y then produce_drug fi (1)

Figure 2: Diagnostics of pathogenic mutations Diagnosis Cancer.jpg
Figure 2: Diagnostics of pathogenic mutations
Figure 3: Therapy of pathogenic mutations Therapy cancer.jpg
Figure 3: Therapy of pathogenic mutations

Such a rule might be implemented by a molecular automaton consisting of two partially dsDNA molecules and one ssDNA molecule, which corresponds to the disease-related mutation and provides a molecular switch for the linear self-assembly of the functional gene (Fig. 2). The gene structure is completed by a cellular ligase present in both eukaryotic and prokaryotic cells. The transcription and translation machinery of the cell is then in charge of therapy and administers either a wild-type protein or an anti-drug (Fig. 3). The rule (1) may even be generalised to involve mutations from different proteins allowing a combined diagnosis and therapy.

In this way, computational genes might allow implementation in situ of a therapy as soon as the cell starts developing defective material. Computational genes combine the techniques of gene therapy which allows to replace in the genome an aberrant gene by its healthy counterpart, as well as to silence the gene expression (similar to antisense technology).

Challenges

Although mechanistically simple and quite robust on molecular level, several issues need to be addressed before an in vivo implementation of computational genes can be considered.

First, the DNA material must be internalised into the cell, specifically into the nucleus. In fact, the transfer of DNA or RNA through biological membranes is a key step in the drug delivery. [8] Some results show that nuclear localisation signals can be irreversibly linked to one end of the oligonucleotides, forming an oligonucleotide-peptide conjugate that allows effective internalisation of DNA into the nucleus. [9]

In addition, the DNA complexes should have low immunogenicity to guarantee their integrity in the cell and their resistance to cellular nucleases. Current strategies to eliminate nuclease sensitivity include modifications of the oligonucleotide backbone such as methylphosphonate [10] and phosphorothioate (S-ODN) oligodeoxynucleotides, [11] but along with their increased stability, modified oligonucleotides often have altered pharmacologic properties. [12]

Finally, similar to any other drug, DNA complexes could cause nonspecific and toxic side effects. In vivo applications of antisense oligonucleotides showed that toxicity is largely due to impurities in the oligonucleotide preparation and lack of specificity of the particular sequence used. [13]

Undoubtedly, progress on antisense biotechnology will also result in a direct benefit to the model of computational genes.[ citation needed ]

See also

Related Research Articles

Protein biosynthesis Assembly of proteins inside biological cells

Protein biosynthesis is a core biological process, occurring inside cells, balancing the loss of cellular proteins through the production of new proteins. Proteins perform a number of critical functions as enzymes, structural proteins or hormones. Protein synthesis is a very similar process for both prokaryotes and eukaryotes but there are some distinct differences.

Peptide nucleic acid Biological molecule

Peptide nucleic acid (PNA) is an artificially synthesized polymer similar to DNA or RNA.

Oligonucleotides are short DNA or RNA molecules, oligomers, that have a wide range of applications in genetic testing, research, and forensics. Commonly made in the laboratory by solid-phase chemical synthesis, these small bits of nucleic acids can be manufactured as single-stranded molecules with any user-specified sequence, and so are vital for artificial gene synthesis, polymerase chain reaction (PCR), DNA sequencing, molecular cloning and as molecular probes. In nature, oligonucleotides are usually found as small RNA molecules that function in the regulation of gene expression, or are degradation intermediates derived from the breakdown of larger nucleic acid molecules.

Gene silencing is the regulation of gene expression in a cell to prevent the expression of a certain gene. Gene silencing can occur during either transcription or translation and is often used in research. In particular, methods used to silence genes are being increasingly used to produce therapeutics to combat cancer and other diseases, such as infectious diseases and neurodegenerative disorders.

Locked nucleic acid Biological molecule

A locked nucleic acid (LNA), also known as bridged nucleic acid (BNA), and often referred to as inaccessible RNA, is a modified RNA nucleotide in which the ribose moiety is modified with an extra bridge connecting the 2' oxygen and 4' carbon. The bridge "locks" the ribose in the 3'-endo (North) conformation, which is often found in the A-form duplexes. This structure can be attributed to the increased stability against enzymatic degradation; moreover the structure of LNA has improved specificity and affinity as a monomer or a constituent of an oligonucleotide. LNA nucleotides can be mixed with DNA or RNA residues in the oligonucleotide, in effect hybridizing with DNA or RNA according to Watson-Crick base-pairing rules.

Site-directed mutagenesis is a molecular biology method that is used to make specific and intentional changes to the DNA sequence of a gene and any gene products. Also called site-specific mutagenesis or oligonucleotide-directed mutagenesis, it is used for investigating the structure and biological activity of DNA, RNA, and protein molecules, and for protein engineering.

Small interfering RNA

Small interfering RNA (siRNA), sometimes known as short interfering RNA or silencing RNA, is a class of double-stranded RNA non-coding RNA molecules, typically 20-24 base pairs in length, similar to miRNA, and operating within the RNA interference (RNAi) pathway. It interferes with the expression of specific genes with complementary nucleotide sequences by degrading mRNA after transcription, preventing translation.

Frameshift mutation Mutation that shifts codon alignment

A frameshift mutation is a genetic mutation caused by indels of a number of nucleotides in a DNA sequence that is not divisible by three. Due to the triplet nature of gene expression by codons, the insertion or deletion can change the reading frame, resulting in a completely different translation from the original. The earlier in the sequence the deletion or insertion occurs, the more altered the protein. A frameshift mutation is not the same as a single-nucleotide polymorphism in which a nucleotide is replaced, rather than inserted or deleted. A frameshift mutation will in general cause the reading of the codons after the mutation to code for different amino acids. The frameshift mutation will also alter the first stop codon encountered in the sequence. The polypeptide being created could be abnormally short or abnormally long, and will most likely not be functional.

Morpholino Chemical compound

A Morpholino, also known as a Morpholino oligomer and as a phosphorodiamidate Morpholino oligomer (PMO), is a type of oligomer molecule used in molecular biology to modify gene expression. Its molecular structure contains DNA bases attached to a backbone of methylenemorpholine rings linked through phosphorodiamidate groups. Morpholinos block access of other molecules to small specific sequences of the base-pairing surfaces of ribonucleic acid (RNA). Morpholinos are used as research tools for reverse genetics by knocking down gene function.

Antisense RNA

Antisense RNA (asRNA), also referred to as antisense transcript, natural antisense transcript (NAT) or antisense oligonucleotide, is a single stranded RNA that is complementary to a protein coding messenger RNA (mRNA) with which it hybridizes, and thereby blocks its translation into protein. asRNAs have been found in both prokaryotes and eukaryotes, and can be classified into short and long non-coding RNAs (ncRNAs). The primary function of asRNA is regulating gene expression. asRNAs may also be produced synthetically and have found wide spread use as research tools for gene knockdown. They may also have therapeutic applications.

Silent mutation

Silent mutations are mutations in DNA that do not have an observable effect on the organism's phenotype. They are a specific type of neutral mutation. The phrase silent mutation is often used interchangeably with the phrase synonymous mutation; however, synonymous mutations are not always silent, nor vice versa. Synonymous mutations can affect transcription, splicing, mRNA transport, and translation, any of which could alter phenotype, rendering the synonymous mutation non-silent. The substrate specificity of the tRNA to the rare codon can affect the timing of translation, and in turn the co-translational folding of the protein. This is reflected in the codon usage bias that is observed in many species. Mutations that cause the altered codon to produce an amino acid with similar functionality are often classified as silent; if the properties of the amino acid are conserved, this mutation does not usually significantly affect protein function.

Triple-stranded DNA DNA structure

Triple-stranded DNA is a DNA structure in which three oligonucleotides wind around each other and form a triple helix. In triple-stranded DNA, the third strand binds to a B-form DNA double helix by forming Hoogsteen base pairs or reversed Hoogsteen hydrogen bonds.

In molecular biology and genetics, the sense of a nucleic acid molecule, particularly of a strand of DNA or RNA, refers to the nature of the roles of the strand and its complement in specifying a sequence of amino acids. Depending on the context, sense may have slightly different meanings. For example, negative-sense strand of DNA is equivalent to the template strand, whereas the positive-sense strand is the non-template strand whose nucleotide sequence is equivalent to the sequence of the mRNA transcript.

Therapeutic gene modulation refers to the practice of altering the expression of a gene at one of various stages, with a view to alleviate some form of ailment. It differs from gene therapy in that gene modulation seeks to alter the expression of an endogenous gene whereas gene therapy concerns the introduction of a gene whose product aids the recipient directly.

Cell-penetrating peptides (CPPs) are short peptides that facilitate cellular intake and uptake of molecules ranging from nanosize particles to small chemical compounds to large fragments of DNA. The "cargo" is associated with the peptides either through chemical linkage via covalent bonds or through non-covalent interactions.

Oblimersen is an antisense oligodeoxyribonucleotide being studied as a possible treatment for several types of cancer, including chronic lymphocytic leukemia, B-cell lymphoma, and breast cancer. It may kill cancer cells by blocking the production of Bcl-2—a protein that makes cancer cells live longer—and by making them more sensitive to chemotherapy.

Natural computing, also called natural computation, is a terminology introduced to encompass three classes of methods: 1) those that take inspiration from nature for the development of novel problem-solving techniques; 2) those that are based on the use of computers to synthesize natural phenomena; and 3) those that employ natural materials to compute. The main fields of research that compose these three branches are artificial neural networks, evolutionary algorithms, swarm intelligence, artificial immune systems, fractal geometry, artificial life, DNA computing, and quantum computing, among others.

In molecular biology, exon skipping is a form of RNA splicing used to cause cells to “skip” over faulty or misaligned sections (exons) of genetic code, leading to a truncated but still functional protein despite the genetic mutation.

Julianna Lisziewicz is a Hungarian immunologist. Lisziewicz headed many research teams that have discovered and produced immunotheraputic drugs to treat diseases like cancer and chronic infections like HIV/AIDS. Some of these drugs have been successfully used in clinical trials.

RNA-targeting small molecules represent a class of small molecules, organic compounds with traditional drug properties that can bind to RNA secondary or tertiary structures and alter translation patterns, localization, and degradation.

References

  1. ↑ Martínez-Pérez, Israel M; Zhang, Gong; Ignatova, Zoya; Zimmermann, Karl-Heinz (2007). "Computational genes: A tool for molecular diagnosis and therapy of aberrant mutational phenotype". BMC Bioinformatics. 8: 365. doi:10.1186/1471-2105-8-365. PMC   2175521 . PMID   17903261.
  2. ↑ DEpatent 102006009000,Zimmermann, Karl-Heinz; Ignatova, Zoya& Martinez-Perez, Israel Marck,"Rechengen [Computer gene]",published 2007-09-06
  3. ↑ Martinez-Perez, I.M. (2007). Biomolecular computing models for graph problems and finite state automata (Ph.D. Thesis). Hamburg, Germany: Hamburg University of Technology. ISBN   978-3-86664-326-0.[ page needed ]
  4. ↑ "Smart Vaccines" – The Shape of Things to Come Archived March 13, 2009, at the Wayback Machine Research Interests, Joshua E. Mendoza-Elias
  5. ↑ Montesano, R.; Hainaut, P.; Wild, C. P. (1997). "Hepatocellular Carcinoma: From Gene to Public Health". JNCI Journal of the National Cancer Institute. 89 (24): 1844–51. doi: 10.1093/jnci/89.24.1844 . PMID   9414172.
  6. ↑ Jackson, P. E.; Kuang, SY; Wang, JB; Strickland, PT; Muñoz, A; Kensler, TW; Qian, GS; Groopman, JD (2003). "Prospective detection of codon 249 mutations in plasma of hepatocellular carcinoma patients". Carcinogenesis. 24 (10): 1657–63. doi: 10.1093/carcin/bgg101 . PMID   12869416.
  7. ↑ Friedler, Assaf; Hansson, Lars O.; Veprintsev, Dmitry B.; Freund, Stefan M. V.; Rippin, Thomas M.; Nikolova, Penka V.; Proctor, Mark R.; Rüdiger, Stefan; Fersht, Alan R. (2002). "A peptide that binds and stabilizes p53 core domain: Chaperone strategy for rescue of oncogenic mutants". Proceedings of the National Academy of Sciences. 99 (2): 937–42. Bibcode:2002PNAS...99..937F. doi: 10.1073/pnas.241629998 . JSTOR   3057669. PMC   117409 . PMID   11782540.
  8. ↑ Lambert, Gregory; Fattal, Elias; Couvreur, Patrick (2001). "Nanoparticulate systems for the delivery of antisense oligonucleotides". Advanced Drug Delivery Reviews. 47 (1): 99–112. doi:10.1016/S0169-409X(00)00116-2. PMID   11251248.
  9. ↑ Zanta, Maria Antonietta; Belguise-Valladier, Pascale; Behr, Jean-Paul (1999). "Gene Delivery: A Single Nuclear Localization Signal Peptide is Sufficient to Carry DNA to the Cell Nucleus". Proceedings of the National Academy of Sciences of the United States of America. 96 (1): 91–6. Bibcode:1999PNAS...96...91Z. doi: 10.1073/pnas.96.1.91 . JSTOR   47127. PMC   15098 . PMID   9874777.
  10. ↑ Miller, PS; Ts'o, PO (1987). "A new approach to chemotherapy based on molecular biology and nucleic acid chemistry: Matagen (masking tape for gene expression)". Anti-Cancer Drug Design. 2 (2): 117–28. PMID   3329522.
  11. ↑ Stec, Wojciech J.; Zon, Gerald; Egan, William (1984). "Automated solid-phase synthesis, separation, and stereochemistry of phosphorothioate analogs of oligodeoxyribonucleotides". Journal of the American Chemical Society. 106 (20): 6077–9. doi:10.1021/ja00332a054.
  12. ↑ Brysch, Wolfgang; Schlingensiepen, Karl-Hermann (1994). "Design and application of antisense oligonucleotides in cell culture,in vivo, and as therapeutic agents". Cellular and Molecular Neurobiology. 14 (5): 557–68. doi:10.1007/BF02088837. PMID   7621513. S2CID   5836570.
  13. ↑ Lebedeva, Irina; Stein, CA (2001). "Antisense oligonucleotides: promise and reality". Annual Review of Pharmacology and Toxicology. 41: 403–19. doi:10.1146/annurev.pharmtox.41.1.403. PMID   11264463.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.